”a phase 3 company priced like a phase 2 company”.
that’s because it is a phase 2 company.
this asset had negligible data in the old phase 2 it’s almost pointless. So the part 1 of this current trial first 70 patients that takes it to the mid Mar futility analysis is effectively the phase 2 that was never done for this asset.
Add to My Watchlist
What is My Watchlist?
